İrem BİLGETEKİN, Kamil GÖNDEREN, Aysun GÖNDEREN, Mehmet YILDIZ

Yeni tanı konulmuş glukoz metabolizma bozukluğu olan hastalarda serum visfatin konsatrasyonunun değerlendirilmesi

Amaç: Visfatin, visseral adipoz doku tarafından salgılanan, insülinmimetik etkileri olan ve plazma glukoz seviyelerini düşüren hücre içi bir enzimdir. Yeni tanı konulan glukoz metabolizma bozukluklarında visfatinin rolü ile ilgili yapılan çalışmalar sınırlıdır. Bu çalışmanın amacı bozulmuş açlık glukozu ve bozulmuş glukoz toleransı olan hastalarda visfatin serum konsantrasyonunu değerlendirmektir. Gereç ve Yöntem: Anormal glukoz metabolizması tanısı alan 57 hasta, oral glukoz tolerans testi sonuçlarına göre bozulmuş açlık glukozu (BAG) (n=39) ve BAG+ bozulmuş glukoz toleransı (BGT) (n=18) olarak alt gruplara ayrıldı. Kontrol grubu, normal glukoz toleransı olan ve herhangi bir metabolik bozukluğu olmayan 44 sağlıklı bireyden oluşuyordu. Tüm katılımcıların serum lipid, yüksek duyarlı C-reaktif protein(hsCRP), ürik asit, glikozile hemoglobin (HbA1c) ve serum visfatin düzeyleri ölçüldü. Bulgular: BAG grubunun visfatin düzeyi 93,92±12,95 ng/mL, BAG+BGT grubunun 37,79±29,36 ng/mL kontrol grubunun 43,96±38,57 ng/mL idi. Grupların serum visfatin düzeyleri arasında istatistiksel olarak anlamlı fark vardı (p

Visfatin concentration in patients with newly-diagnosed glucose metabolism disorders

Purpose: Visfatin, protein secreted by visceral adipose tissue, visfatin is an intracellular enzyme that has insulinmimetic effects and lowers plasma glucose levels. Data about the role of visfatin in newly diagnosed glucose metabolism abnormalities are limited. The aim of the work was to assess serum concentration of visfatin in impaired fasting glucose and impaired glucose tolerance. Materials and Methods: With diagnosis of abnormal glucose metabolism 57 patients were divided into the subgroups according to the oral glucose tolerance test results as impaired fasting glucose (n=39) and impaired fasting glucose+impaired glucose tolerance (n=18). The control group consisted of 44 healthy controls with normal glucose tolerance and without any metabolic disorders. Serum lipids, high sensitive C-reactive protein(hsCRP), uric acid, glycated haemoglobin (HbA1c) and serum visfatin levels were measured in all participants. Results: The mean visfatin level of impaired fasting glucose group was 93.92±12.95 ng/mL, impaired fasting glucose+impaired glucose tolerance group was 37.79±29.36 ng/mL and control group was 43.96±38.57 ng/ mL. There was statistically significant difference between serum visfatin levels of the groups (p

PDF

___

1. Genuth S, Alberti KG, Bennett P, et al. Follow-up report on the diagnosis of diabetes mellitus. Diabetes Care 2003;26:3160-3167. https://doi.org/10.2337/ diacare.26.11.3160
2. Diabetes mellitus çalışma ve eğitim grubu, Türkiye Endokrinoloji ve Metabolizma Derneği, Diabetes mellitus ve komplikasyonlarının tanı, tedavi ve izlem kılavuzu- Güncellenmiş 12. baskı 2019;15-22.
3. McGee KC, Harte AL, daSilva NF, et al. Visfatin is regulated by rosiglitazone in type 2 diabetes mellitus and influenced by NFkb and JNK in Human Abdominal Subcutaneous Adipocytes. PLoS one 2011;6:20287.
4. Ognjanovic S, Bao S, Yamamoto SY, Garibay- Tupas J, Samal B, Bryant-Greenwood GD. Genomic organization of the gene coding for human pre-B-cell colony enhancing factor and expression in human fetal membranes. J Mol Endocrinol 2001;26:107-117.
5. Chang YH, Chang DM, Lin KC, Shin SJ, Lee YJ. Visfatin in overweight/obesity, type 2diabetes mellitus, insulin resistance, metabolic syndrome and cardiovascular diseases: A meta-analysis and systemic review. Diabetes Metab Res Rev 2011;27:515-527. https://doi. org/10.1002/dmrr.1201
6. Matthews DR, Hosker JP, Rudenski AS, Naylor BA, Treacher DF, Turner RC. Homeostasis model assessment: Insulin resistance and beta-cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia 1985;28:412-419.
7. Wallace TM, Levy JC, Matthews DR. Use and abuse of HOMA modeling. Diabetes Care. 2004;27:1487-1495.
8. Lopez-Bermejo A, Chico-Julia B, Fernandez-Balsells M, et al. Serum visfatin increases with progressive beta-cell deterioration. Diabetes 2006;55:2871-2875 https://doi.org/10.2337/db06-0259
9. Brown JE, Onyango DJ, Ramanjaneya M, et al. Visfatin regulates insulin secretion, insulin receptor signalling and mRNA expression of diabetes-related genes in mouse pancreatic beta-cells. J Mol Endocrinol 2010;44:171-178. https://doi.org/10.1677/JME-09- 0071
10. Chen MP, Chung FM, Chang DM, et al. Elevated plasma level of visfatin/pre-B cell colony-enhancing factor in patients with type 2 diabetes mellitus. J Clin Endocrinol Metab 2006;91:295-299. https://doi. org/10.1210/jc.2005-1475
11. Krzyzanowska K, Krugluger W, Mittermayer F, et al. Increased visfatin concentrations in women with gestational diabetes mellitus. Clin Sci (Lond) 2006;110:605-609. https://doi.org/10.1042/ CS20050363
12. Stephens JM, Vidal-Puig AJ. An update on visfatin/ pre-B cell colonyenhancing factor, a ubiquitously expressed, illusive cytokine that is regulated in obesity. Curr Opin Lipidol 2006;17:128-131. https://doi. org/10.1097/01.mol.0000217893.77746.4b
13. Toruner F, Altinova AE, Bukan N, et al. Plasma visfatin concentrations in subjects with type 1 diabetes mellitus. Horm Res 2009;72:33-37. https://doi. org/10.1159/000224338
14. Nüsken KD, Nüsken E, Petrasch M, et al. Preanalytical influences on the measurement of visfatin by enzyme immuno assay. Clin Chim Acta 2007;382:154-156. https://doi.org/10.1016/j.cca.2007.04.004
15. Oki K, Yamane K, Kamei N, et al. Circulating visfatin level is correlated with inflammation, but not with insulin resistance. Clin Endocrinol 2007;67:796-800.
16. Körner A, Garten A, Blüher M, et al. Molecular characteristics of serum visfatin and differential detection by immunoassays. J Clin Endocrinol Metab 2007;92:4783-4791. https://doi.org/10.1210/jc.2007- 1304
17. Zahorska-Markiewicz B, Olszanecka-Glinianowicz M,Janowska J, et al. Serum concentration of visfatin in obese women. Metabolism 2007;56:1131-1134. https://doi.org 10.1016/j.metabol.2007.04.007
18. Kamińska A, Kopczyńska E, Bronisz A, et al. An evaluation of visfatin levels in obese subjects. Endokrynol Pol 2010;61:169-173.
19. Davutoglu M, Ozkaya M, Guler E, et al. Plasma visfatin concentrations in childhood obesity: relationships to insulin resistance and anthropometric indices. Swiss Med Wkly 2009;139:22-27. https://doi.org smw-12400
20. Berndt J, Klöting N, Kralisch S, et al. Plasma visfatin concentrations and fat depot-specific mRNA expression in humans. Diabetes 2005;54:2911-2916.
21. Pagano C, Pilon C, Olivieri M, et al. Reduced plasma visfatin/pre B-cell colony enhancing factor in obesity is not related to insulin resistance in humans. J Clin Endocrinol Metab 2006;91:3165-3170. https://doi.org 10.1210/jc.2006-0361